Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents
Highlights • In RCTs, gliclazide lowered HbA1c more than other oral insulinotropic agents. • Patients taking a DPP-4i or gliclazide have similarly low risks of Hypoglycemia. • National guidelines advocate gliclazide over other SUs for better CV and hypoglycemic safety.
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2015-10, Vol.110 (1), p.75-81 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 81 |
|---|---|
| container_issue | 1 |
| container_start_page | 75 |
| container_title | Diabetes research and clinical practice |
| container_volume | 110 |
| creator | Chan, Siew Pheng Colagiuri, Stephen |
| description | Highlights • In RCTs, gliclazide lowered HbA1c more than other oral insulinotropic agents. • Patients taking a DPP-4i or gliclazide have similarly low risks of Hypoglycemia. • National guidelines advocate gliclazide over other SUs for better CV and hypoglycemic safety. |
| doi_str_mv | 10.1016/j.diabres.2015.07.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1721347194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0168822715003198</els_id><sourcerecordid>1721347194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-f4d497692dc5af3485009007cd2bddc5f361af13bacfd9d23ac3b53bb15c57b73</originalsourceid><addsrcrecordid>eNqFkcuO1DAQRS0EYpqBTwBlySbBjyRONiA04iWNxGJgbTl2uceNkzQuZ1AQH48z3bBgw8qWdW5ZdS4hzxmtGGXtq0NlvR4iYMUpayoqK0r5A7JjneRlx7l8SHaZ6-7vF-QJ4oFS2oq6eUwueCta1jX9jvy6WTHBqJM3RYQ7Dz8KPdlihKRLPemwosdidkW6hQKc80ab9Z64XY_zPqwGxpxE7SCtG7cP3gT901so7iDiksM5Ggs_4RL8NKc4H3NA72FK-JQ8cjogPDufl-Tr-3dfrj6W158_fLp6e12auqepdLWte9n23JpGO1F3DaU9pdJYPtj85vIy2jExaONsb7nQRgyNGAbWmEYOUlySl6e5xzh_XwCTGj0aCEFPMC-omORM1JL1dUabE2rijBjBqWP0o46rYlRt4tVBncWrTbyiUmXxOffi_MUyjGD_pv6YzsCbEwB50ew5KjQeJgPWRzBJ2dn_94vX_0ww2WhuJHyDFfAwLzEXlrdRyBVVN1v7W_ks6xKs78Rv6LmvPQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1721347194</pqid></control><display><type>article</type><title>Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chan, Siew Pheng ; Colagiuri, Stephen</creator><creatorcontrib>Chan, Siew Pheng ; Colagiuri, Stephen</creatorcontrib><description>Highlights • In RCTs, gliclazide lowered HbA1c more than other oral insulinotropic agents. • Patients taking a DPP-4i or gliclazide have similarly low risks of Hypoglycemia. • National guidelines advocate gliclazide over other SUs for better CV and hypoglycemic safety.</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2015.07.002</identifier><identifier>PMID: 26361859</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Efficacy ; Endocrinology & Metabolism ; Gliclazide ; Gliclazide - adverse effects ; Gliclazide - therapeutic use ; Glyburide - therapeutic use ; Glycated Hemoglobin A - analysis ; Humans ; Hypoglycemia ; Hypoglycemia - chemically induced ; Hypoglycemia - epidemiology ; Hypoglycemic Agents - therapeutic use ; Insulinotropic ; Meta-analysis ; Metformin - therapeutic use ; Middle Aged ; Randomized Controlled Trials as Topic - statistics & numerical data ; Sulfonylurea Compounds - therapeutic use ; Systematic review ; Treatment Outcome ; Young Adult</subject><ispartof>Diabetes research and clinical practice, 2015-10, Vol.110 (1), p.75-81</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-f4d497692dc5af3485009007cd2bddc5f361af13bacfd9d23ac3b53bb15c57b73</citedby><cites>FETCH-LOGICAL-c490t-f4d497692dc5af3485009007cd2bddc5f361af13bacfd9d23ac3b53bb15c57b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168822715003198$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26361859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chan, Siew Pheng</creatorcontrib><creatorcontrib>Colagiuri, Stephen</creatorcontrib><title>Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>Highlights • In RCTs, gliclazide lowered HbA1c more than other oral insulinotropic agents. • Patients taking a DPP-4i or gliclazide have similarly low risks of Hypoglycemia. • National guidelines advocate gliclazide over other SUs for better CV and hypoglycemic safety.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Efficacy</subject><subject>Endocrinology & Metabolism</subject><subject>Gliclazide</subject><subject>Gliclazide - adverse effects</subject><subject>Gliclazide - therapeutic use</subject><subject>Glyburide - therapeutic use</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hypoglycemia</subject><subject>Hypoglycemia - chemically induced</subject><subject>Hypoglycemia - epidemiology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulinotropic</subject><subject>Meta-analysis</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Randomized Controlled Trials as Topic - statistics & numerical data</subject><subject>Sulfonylurea Compounds - therapeutic use</subject><subject>Systematic review</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuO1DAQRS0EYpqBTwBlySbBjyRONiA04iWNxGJgbTl2uceNkzQuZ1AQH48z3bBgw8qWdW5ZdS4hzxmtGGXtq0NlvR4iYMUpayoqK0r5A7JjneRlx7l8SHaZ6-7vF-QJ4oFS2oq6eUwueCta1jX9jvy6WTHBqJM3RYQ7Dz8KPdlihKRLPemwosdidkW6hQKc80ab9Z64XY_zPqwGxpxE7SCtG7cP3gT901so7iDiksM5Ggs_4RL8NKc4H3NA72FK-JQ8cjogPDufl-Tr-3dfrj6W158_fLp6e12auqepdLWte9n23JpGO1F3DaU9pdJYPtj85vIy2jExaONsb7nQRgyNGAbWmEYOUlySl6e5xzh_XwCTGj0aCEFPMC-omORM1JL1dUabE2rijBjBqWP0o46rYlRt4tVBncWrTbyiUmXxOffi_MUyjGD_pv6YzsCbEwB50ew5KjQeJgPWRzBJ2dn_94vX_0ww2WhuJHyDFfAwLzEXlrdRyBVVN1v7W_ks6xKs78Rv6LmvPQ</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Chan, Siew Pheng</creator><creator>Colagiuri, Stephen</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents</title><author>Chan, Siew Pheng ; Colagiuri, Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-f4d497692dc5af3485009007cd2bddc5f361af13bacfd9d23ac3b53bb15c57b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Efficacy</topic><topic>Endocrinology & Metabolism</topic><topic>Gliclazide</topic><topic>Gliclazide - adverse effects</topic><topic>Gliclazide - therapeutic use</topic><topic>Glyburide - therapeutic use</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hypoglycemia</topic><topic>Hypoglycemia - chemically induced</topic><topic>Hypoglycemia - epidemiology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulinotropic</topic><topic>Meta-analysis</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Randomized Controlled Trials as Topic - statistics & numerical data</topic><topic>Sulfonylurea Compounds - therapeutic use</topic><topic>Systematic review</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chan, Siew Pheng</creatorcontrib><creatorcontrib>Colagiuri, Stephen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chan, Siew Pheng</au><au>Colagiuri, Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>110</volume><issue>1</issue><spage>75</spage><epage>81</epage><pages>75-81</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract>Highlights • In RCTs, gliclazide lowered HbA1c more than other oral insulinotropic agents. • Patients taking a DPP-4i or gliclazide have similarly low risks of Hypoglycemia. • National guidelines advocate gliclazide over other SUs for better CV and hypoglycemic safety.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>26361859</pmid><doi>10.1016/j.diabres.2015.07.002</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2015-10, Vol.110 (1), p.75-81 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1721347194 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Efficacy Endocrinology & Metabolism Gliclazide Gliclazide - adverse effects Gliclazide - therapeutic use Glyburide - therapeutic use Glycated Hemoglobin A - analysis Humans Hypoglycemia Hypoglycemia - chemically induced Hypoglycemia - epidemiology Hypoglycemic Agents - therapeutic use Insulinotropic Meta-analysis Metformin - therapeutic use Middle Aged Randomized Controlled Trials as Topic - statistics & numerical data Sulfonylurea Compounds - therapeutic use Systematic review Treatment Outcome Young Adult |
| title | Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T22%3A42%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systematic%20review%20and%20meta-analysis%20of%20the%20efficacy%20and%20hypoglycemic%20safety%20of%20gliclazide%20versus%20other%20insulinotropic%20agents&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Chan,%20Siew%20Pheng&rft.date=2015-10-01&rft.volume=110&rft.issue=1&rft.spage=75&rft.epage=81&rft.pages=75-81&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2015.07.002&rft_dat=%3Cproquest_cross%3E1721347194%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1721347194&rft_id=info:pmid/26361859&rft_els_id=1_s2_0_S0168822715003198&rfr_iscdi=true |